“Brookstone is known for selling leading edge technology,” said Shai N.
Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “We are pleased
to be working with Brookstone to broaden the availability of our Quell
proprietary, 100% drug free technology for the relief of widespread
Quell is FDA cleared and designed for millions of people suffering from
chronic pain. The latest version of Quell gives users the option to
start, stop, and adjust therapy discreetly via their smartphone. It also
enables advanced sleep tracking that provides feedback on multiple
dimensions of sleep including sleep duration, quality, body position,
time out of bed, and repetitive leg movements throughout the night. In
addition to Brookstone.com, Quell is available at Target, select
healthcare professionals and retailers, and at www.quellrelief.com.
Brookstone is a nationwide specialty retailer offering an assortment of
consumer products that are functional in purpose, distinctive in quality
and design and not widely available from other retailers. In addition to
their website, Brookstone operates more than 200 retail stores
throughout the United States and Puerto Rico, primarily in premium
shopping malls, lifestyle centers and the nation’s busiest airports.
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer